COMPOUND PROFILE / SMALL MOLECULES
Danuglipron.
Research draftDanuglipron is an oral small-molecule GLP-1 receptor agonist formerly developed for metabolic disease.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
Danuglipron is an oral small-molecule GLP-1 receptor agonist formerly developed for metabolic disease.
Mechanism
It activates GLP-1 receptors without a peptide structure.
Human research
Randomised diabetes and obesity studies showed metabolic activity, with substantial tolerability-related discontinuation in development.
Preclinical & other research
Laboratory work characterised oral receptor activity.
Safety & unknowns
Gastrointestinal burden and a development liver-safety concern are material limitations.
Regulatory status
Pfizer announced discontinuation of development; a promising trial result does not establish approval.
Reported use & evidence
The supplied Danuglipron profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.